Every Form 4 that Kodiak Sciences Inc (KOD) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow KOD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KOD filings page.
Kodiak Sciences Inc. reported a compensation grant to Chief Financial Officer John A. Borgeson of stock options covering 66,500 shares of common stock on July 15, 2026. The options have an exercise price of $42.42 per share, expire on July 14, 2036, and were fully unvested at grant. One-forty-eighth of the shares vest one month after July 1, 2026, with the remaining shares vesting in forty-seven equal monthly installments thereafter, subject to his Continuous Service under the 2018 Equity Incentive Plan.
Kodiak Sciences Inc. reported that Chairman, CEO and 10% owner Victor Perlroth received a grant of stock options covering 100,000.0000 shares of Common Stock at an exercise price of $42.4200 per share. These options expire on 2036-07-14 and vest monthly beginning after July 1, 2026, subject to his Continuous Service.
Kodiak Sciences Inc. director Yang Taiyin received a new stock option grant as part of equity compensation. The award covers 17,731 stock options for common stock at an exercise price of $38.96 per share, with no cash paid at grant.
All 17,731 options will vest in a single tranche on the earlier of June 30, 2027 or one day before Kodiak Sciences’ next annual shareholder meeting after the grant date, provided Yang continues serving on the board through the applicable vesting date. Following this grant, Yang holds 17,731 stock options directly.
Kodiak Sciences Inc. director Robert Profusek received a grant of stock options covering 17,731 shares of common stock. The options have an exercise price of $38.96 per share and expire on June 29, 2036.
All 17,731 option shares vest in full on the earlier of June 30, 2027 or one day before the company’s next annual meeting after the grant date, as long as he continues serving on the board through that vesting date. Following this grant, he holds 17,731 derivative securities directly.
Kodiak Sciences Inc. director Richard S. Levy received a stock option grant covering 17,731 shares of common stock. The option has an exercise price of $38.96 per share and expires on June 29, 2036. Following this grant, he holds options for 17,731 shares directly.
All 17,731 option shares will vest in a single tranche on the earlier of June 30, 2027 or one day before Kodiak Sciences’ next annual shareholder meeting after the grant date, provided Levy continues to serve on the board of directors through the applicable vesting date.
Kodiak Sciences Inc. director Bassil I. Dahiyat received a grant of stock options covering 17,731 shares of common stock. The options have an exercise price of $38.96 per share and expire on June 29, 2036.
All 17,731 option shares vest in a single tranche on the earlier of June 30, 2027 or one day before Kodiak’s next annual shareholder meeting after the grant date, provided Dahiyat continues to serve on the board through that vesting date.
Kodiak Sciences director Charles A. Bancroft received a new stock option grant, giving him the right to buy 17,731 shares of common stock at an exercise price of $38.96 per share. These options were granted at no cost to him on June 30, 2026.
The entire option grant vests in a single tranche on the earlier of June 30, 2027 or one day before Kodiak Sciences’ next annual shareholder meeting after the grant date, as long as Bancroft continues to serve on the company’s board of directors through that vesting date. After this grant, he holds options for 17,731 shares directly.
BAKER BROS. ADVISORS LP reported acquisition or exercise transactions in this Form 4 filing.
Kodiak Sciences Inc. reported a compensation-related insider transaction involving a grant of non-qualified stock options linked to entities associated with Julian and Felix Baker. On June 30, 2026, Felix J. Baker, serving as a director, received a grant of 17,731 stock options exercisable into Kodiak common stock at a strike price of $38.96 per share under the company’s 2018 Equity Incentive Plan. The options vest on the earlier of the first anniversary of the grant or one day before the next annual stockholder meeting, provided he continues serving on the board, and they expire on June 29, 2036. The grant is reported for multiple Baker-affiliated funds because each has an indirect proportionate pecuniary interest, while Baker Bros. Advisors LP holds voting and dispositive power and the Baker parties and the adviser disclaim beneficial ownership beyond their economic interest.
Kodiak Sciences Inc. Chief Financial Officer John A. Borgeson reported an exercise-and-sell transaction in company stock. He exercised stock options for 30,000 shares of common stock at an exercise price of $1.04 per share and acquired those shares. On the same date, he sold a total of 30,000 shares of common stock in open-market transactions at weighted-average prices of $34.01 and $34.67 per share, as disclosed in two sale entries. These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 29, 2025. After these transactions, he directly holds 211,930 shares of Kodiak Sciences common stock.
Kodiak Sciences Inc. Chief Financial Officer John A. Borgeson exercised stock options to acquire 28,614 shares of common stock at an exercise price of $1.04 per share. Following the transaction, he directly owns 211,930 common shares and holds options for 30,000 additional shares. The options exercised were already fully vested, indicating this was a routine compensation-related exercise rather than an open-market purchase or sale.
Kodiak Sciences Inc. Chief Financial Officer John A. Borgeson reported an exercise-and-sell transaction involving company stock. On April 2, 2026, he exercised stock options to acquire 30,000 shares of Common Stock at an exercise price of $1.04 per share. The option was fully vested and scheduled to expire on June 22, 2026.
On the same date, he sold a total of 30,000 Common shares in multiple open-market transactions at weighted-average prices of $39.14, $40.29, $40.88, and $41.77 per share. These sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on September 29, 2025. After these transactions, Borgeson directly holds 183,316 shares of Kodiak Sciences Common Stock.
Kodiak Sciences Chairman and CEO Victor Perlroth exercised stock options for 300,000 shares of Common Stock at an exercise price of $1.0400 per share. These options were fully vested at the time of exercise. Following the transaction, he directly holds 2,395,538 shares of Common Stock. No open-market sales were reported in this filing, and the derivative position tied to this specific option grant has been fully converted into common shares.
Kodiak Sciences Inc. reported that Chairman and CEO Victor Perlroth received a grant of stock options covering 175,000 shares of common stock. The options have an exercise price of $25.0000 per share and expire on March 17, 2036.
The award is performance-based. Vesting will be determined by the 30-day average stock price as of June 30, 2027, defined as the Performance Criteria Achievement Date. If the average price is less than $25.00, none of the options vest; at or above $25.00, one-third vests; above $30.00, two-thirds vests; and above $35.00, all 175,000 options vest, subject to Perlroth continuing as a service provider on that date.